ALLAKOS INC. DL-,001 Aktie Logo
US01671P1003
A2JQTK
ALLK

ALLAKOS INC. DL-,001 Aktie

Forecast

The analysts' average price target is €99.79 (+39,816.00%). The median is €99.79 (+39,816.00%).

Buy
  5
Hold
  5
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, ALLAKOS INC. DL-,001 Aktie had revenue of €0 and net profit of -€111.3m

(EUR) 2024
YoY
Revenue 0 -
Gross profit -7.42m 33.62%
Net profit -111.3m 33.74%
EBITDA -103.88m 39.53%

Fundamentals

Metric Value
Market capitalization
€27.11m
Number of shares
90.38m
52-week high/low
€1.42 - €0.20
Dividends No
Beta
0.14
P/E ratio
-0.25
PEG ratio
0.00
P/B ratio
0.37
P/S ratio
0.00

Company profile

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Name
ALLAKOS INC. DL-,001 Aktie
CEO
Robert Alexander
Headquarters San Carlos, ca
USA
Website
Sector
Materials
Industry
Chemicals
IPO
19/07/2018
Employees 131

Ticker symbols

Exchange Symbol
NASDAQ
ALLK
Frankfurt
37Z.F
DĂŒsseldorf
37Z.DU
MĂŒnchen
37Z.MU
đŸȘ

Parqet  uses cookies. Learn more